BOSTON--(BUSINESS WIRE)--Fuze, the leading cloud-based communications platform provider for the modern global enterprise, today announced that it has won two Aragon Research awards––the 2019 ...
TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by ...
BOSTON--(BUSINESS WIRE)--Fuze, the leading cloud-based communications provider for the modern global enterprise, today unveiled their fully integrated contact center as a service (CCaaS) solution, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Boston-based company has made changes to its leadership ...